New combo therapy trial aims for better control of bleeding disorder
NCT ID NCT07278908
Summary
This study is testing if adding a vitamin A-related drug (all-trans retinoic acid) to a standard platelet-boosting drug (avatrombopag) works better for controlling immune thrombocytopenia (ITP) than the standard drug alone. It will involve about 248 adults whose ITP did not fully respond to or came back after first treatments. The goal is to see if the combination helps patients maintain safe platelet levels and potentially stop treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ITP - IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.